Shares of ADMA Biologics Inc (NASDAQ:ADMA) have been assigned a consensus rating of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $10.50.

Several analysts recently commented on the stock. ValuEngine raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a report on Thursday, July 26th. Oppenheimer assumed coverage on shares of ADMA Biologics in a report on Thursday, July 12th. They set a “buy” rating and a $13.00 target price for the company. Maxim Group reaffirmed a “buy” rating and set a $12.00 target price on shares of ADMA Biologics in a report on Wednesday. Raymond James reaffirmed a “buy” rating and set a $10.00 target price (down previously from $11.00) on shares of ADMA Biologics in a report on Friday, October 12th. Finally, BidaskClub downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th.

Shares of ADMA stock traded down $0.05 during midday trading on Friday, hitting $5.53. 305,314 shares of the company were exchanged, compared to its average volume of 238,030. The company has a market capitalization of $258.63 million, a price-to-earnings ratio of -2.90 and a beta of 2.35. The company has a debt-to-equity ratio of 0.79, a quick ratio of 8.88 and a current ratio of 10.65. ADMA Biologics has a 52 week low of $2.01 and a 52 week high of $6.96.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Friday, August 10th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The company had revenue of $4.66 million for the quarter, compared to the consensus estimate of $5.35 million. ADMA Biologics had a negative return on equity of 89.78% and a negative net margin of 119.34%. Sell-side analysts forecast that ADMA Biologics will post -1.34 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. AMP Capital Investors Ltd bought a new stake in ADMA Biologics in the 2nd quarter valued at about $109,000. Element Capital Management LLC bought a new stake in ADMA Biologics in the 1st quarter valued at about $118,000. Renaissance Technologies LLC bought a new stake in ADMA Biologics in the 2nd quarter valued at about $132,000. Schwab Charles Investment Management Inc. bought a new stake in ADMA Biologics in the 2nd quarter valued at about $160,000. Finally, Spark Investment Management LLC boosted its holdings in ADMA Biologics by 68.7% in the 2nd quarter. Spark Investment Management LLC now owns 37,460 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 15,260 shares during the period. 55.08% of the stock is owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Read More: Discount Rate

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.